CTC Alternative Strategies Ltd. Takes Position in Pfizer Inc. $PFE

CTC Alternative Strategies Ltd. purchased a new stake in shares of Pfizer Inc. (NYSE:PFE) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 219,860 shares of the biopharmaceutical company’s stock, valued at approximately $5,571,000. Pfizer accounts for about 6.8% of CTC Alternative Strategies Ltd.’s portfolio, making the stock its 2nd biggest holding.

Several other large investors have also made changes to their positions in the company. Ashton Thomas Private Wealth LLC lifted its stake in shares of Pfizer by 5.5% during the first quarter. Ashton Thomas Private Wealth LLC now owns 48,447 shares of the biopharmaceutical company’s stock valued at $1,228,000 after acquiring an additional 2,514 shares during the period. Guardian Partners Inc. lifted its stake in shares of Pfizer by 14.0% during the first quarter. Guardian Partners Inc. now owns 146,711 shares of the biopharmaceutical company’s stock valued at $3,718,000 after acquiring an additional 18,060 shares during the period. Kestra Investment Management LLC lifted its stake in shares of Pfizer by 38.6% during the first quarter. Kestra Investment Management LLC now owns 81,290 shares of the biopharmaceutical company’s stock valued at $2,060,000 after acquiring an additional 22,619 shares during the period. CKW Financial Group lifted its stake in shares of Pfizer by 126.3% during the first quarter. CKW Financial Group now owns 2,050 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 1,144 shares during the period. Finally, Coordinated Financial Services Inc. CO acquired a new position in shares of Pfizer during the first quarter valued at $222,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on PFE. Morgan Stanley upped their price target on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. HSBC cut their target price on Pfizer from $27.00 to $26.00 and set a “buy” rating on the stock in a research note on Monday, May 19th. Citigroup increased their target price on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Bank of America increased their target price on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Finally, Jefferies Financial Group increased their target price on Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday, May 21st. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $28.12.

Pfizer Stock Up 1.3%

Shares of Pfizer stock opened at $24.86 on Monday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The business has a 50-day moving average of $24.85 and a two-hundred day moving average of $24.34. The company has a market capitalization of $141.31 billion, a P/E ratio of 13.22, a price-to-earnings-growth ratio of 0.88 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the prior year, the company earned $0.60 earnings per share. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. The ex-dividend date was Friday, July 25th. Pfizer’s dividend payout ratio is 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.